Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 8, 2024
Context: This filing discloses insider trading transactions by board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. It also serves as an amendment to a previous announcement (No. 82/2024) regarding a pricing error.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of ADRs |
| Instrument | Novo Nordisk ADRs (NVO) |
| Volume | 1,400 ADRs |
| Price per ADR | DKK 753.02 |
| Total Value | DKK 1,054,226.88 |
| Transaction Date | November 6, 2024 |
| Exchange | New York Stock Exchange |
Material Changes and Amendments
The filing explicitly notes an amendment to Company Announcement No. 82/2024. The previous announcement erroneously stated a transaction price of DKK 697.24. This filing corrects the price to DKK 753.02 for the transaction involving 1,400 ADRs.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on business strategy, or discussion of risks and contingencies. It includes a standard corporate description stating Novo Nordisk is a global healthcare company founded in 1923, employing approximately 69,000 people in 80 countries, with a focus on defeating serious chronic diseases.
Investor Verification Checklist
- Verify the corrected transaction price of DKK 753.02 against the erroneous DKK 697.24 previously reported in Announcement No. 82/2024.
- Confirm the identity of the transacting party: Choi Lai Christina Law, Member of the Board of Directors.
- Note that this filing represents a purchase of 1,400 ADRs on the NYSE on November 6, 2024.
- Recognize that this document does not provide quarterly or annual financial results; refer to Form 20-F or quarterly reports for financial metrics.